Welcome. Ongoing research is needed to find treatment options that may help to increase
long-term survival for ovarian cancer. That’s why we’ve developed the FAR-131 clinical
research study—to investigate a potential treatment for ovarian cancer patients
who have relapsed between 6 and 24 months after treatment with a platinum-containing
chemotherapy regimen.
Thank you for your interest in the FAR-131 study. At this time we are no longer recruiting patients for this study.